Targeted Delivery of mGluR5 Agonists via Engineered hucMSC-Derived EVs to Enhance Macrophage Function and Mitigate Glutamate-Induced Toxicity
- 19 August 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
Abstract
Extracellular vesicles (EVs) are emerging as a potential drug delivery system for neuroinflammatory diseases due to their ability to navigate natural barriers, maintain stability, and facilitate cell-cell signaling. However, their limited targeting ability often restricts their therapeutic efficacy, necessitating enhancements to enable precise targeting of crucial macrophage cells. To address this issue, we genetically modified EVs derived from human umbilical cord mesenchymal stem cells (hucMSCs) using a glycosylated pcDNA3.1-GNSTM-RGV-Lamp2b-HA plasmid to enhance targeted drug delivery to nAchR-expressing macrophages. Through the optimization of hucMSC isolation and transfection protocols, we produced high-yield, surface-modified EVs. Ζ-potential analysis confirmed the stability of these modified EVs, which retained their inherent characteristics, including size, membrane protein expression (TSG101, Flotillin), and morphology. Further, coculture experiments with macrophages evaluated the uptake of modified EVs labeled with PKH67, showing significantly enhanced macrophage uptake. To validate their use in targeted drug delivery, we loaded the EVs with (R, S)-2-chloro-5-hydroxyphenylglycine (CHPG), which is a mGluR5 agonist. We noted that CHPG-loaded EVs increased macrophage proliferation, enhanced macrophage migration, and significantly reduced wound open area in coculture assays. Furthermore, CHPG-loaded modified EVs reduced macrophage cell death and facilitated macrophage entry into the S-phase, mitigating oxidative stress-induced cell cycle arrest under glutamate toxicity. Together, these results highlight the therapeutic potential of hucMSC-derived EV-based drug delivery systems for treating neuroinflammatory and neurodegenerative diseases.Keywords
Funding Information
- Indian Council of Medical Research (R. 5/4-4/18/mh/2022-NCD-11)
- Department of Health Research, India (R.11013/66/2021-GIA/HR)
This publication has 57 references indexed in Scilit:
- Mesenchymal stem cell‐derived extracellular vesicles: Recent therapeutics and targeted drug delivery advancesJournal of Extracellular Biology, 2024
- High Throughput and Highly Controllable Methods for In Vitro Intracellular DeliverySmall, 2020
- Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancerActa Biomaterialia, 2020
- Paclitaxel incorporated exosomes derived from glioblastoma cells: comparative study of two loading techniquesDARU Journal of Pharmaceutical Sciences, 2019
- Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acute liver failure by reducing the activity of the NLRP3 inflammasome in macrophagesBiochemical and Biophysical Research Communications, 2019
- NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injuryBrain, Behavior, and Immunity, 2016
- Novel mGluR5 Positive Allosteric Modulator Improves Functional Recovery, Attenuates Neurodegeneration, and Alters Microglial Polarization after Experimental Traumatic Brain InjuryNeurotherapeutics, 2014
- MiR-133b Promotes Neural Plasticity and Functional Recovery After Treatment of Stroke with Multipotent Mesenchymal Stromal Cells in Rats Via Transfer of Exosome-Enriched Extracellular ParticlesStem Cells, 2013
- Neuroinflammation after traumatic brain injury: Opportunities for therapeutic interventionBrain, Behavior, and Immunity, 2012
- Metabotropic glutamate receptors are expressed in adult human glial progenitor cellsBiochemical and Biophysical Research Communications, 2004